Quadruple therapy with vonoprazan 20mg daily as a first‐line treatment for Helicobacter pylori infection: A single‐center, open‐label, noninferiority, randomized controlled trial

BackgroundAlthough vonoprazan has been proven to be a highly potent drug for Helicobacter pylori eradication, there have been no randomized trials comparing the effectiveness of regimens containing vonoprazan 20 mg daily with alternative standard strategies. We aimed to assess the efficacy, tolerance, and cost‐effectiveness of quadruple therapy with vonoprazan 20 mg daily as a first‐line therapy for H. pylori eradication.Materials and MethodsWe conducted a single‐center, open‐label, noninferiority, randomized controlled study in Zhejiang, China. Treatment‐naive H. pylori‐positive participants (n = 234) were randomly assigned to three groups in a 1:1:1 ratio: vonoprazan 20 mg daily with amoxicillin 1000 mg, furazolidone 100 mg and colloidal bismuth 200 mg each given twice a day for 10 days (V10) or 14 days (V14), or esomeprazole 20 mg with amoxicillin 1000 mg, furazolidone 100 mg and colloidal bismuth 200 mg each given twice a day for 14 days (E14). The primary endpoint was the eradication rates in each group. The secondary endpoints were the incidence of adverse events (AEs) and compliance.ResultsThe eradication rates in the V10, V14 and E14 groups were 96.2% (89.2–99.2%), 94.9% (87.4–98.6%), and 93.6% (85.7–97.9%) in the intention‐to‐treat analysis, and 98.6% (92.7–100.0%), 97.4% (90.8–99.7%), and 94.8% (87.2–98.6%) in the per‐protocol analysis, respectively. Quadruple therapy with vonoprazan 20 mg daily was noninferior to the esomeprazole‐based regimen (Farrington and Manning test: margin 10%, significance level 2.5%). The adverse event rates were 12.8% versus 3.8% versus 6.4% in the V10, V14, and E14 groups, respectively. All regimens were well tolerated without significant differences (p = 0.096). The cost‐effectiveness ratio was 1.32, 1.88, and 3.06 for the V10, V14, and E14 groups in the intention‐to‐treat analysis, respectively. (NCT04907747).ConclusionsVonoprazan (20 mg daily) was as effective as esomeprazole (20 mg twice a day) in quadruple therapies for the eradication of H. pylori, was more economical, and was well tolerated. In addition, the 10‐day regimen of vonoprazan (20 mg daily) was comparable to the 14‐day regimen.